Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+1-617-9969058
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees22
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) announced its quarterly earnings data on Monday, November, 5th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The business earned $0.61 million during the quarter, compared to analyst estimates of $0.82 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 equities research analysts have issued 12 month price objectives for Myomo's shares. Their forecasts range from $7.00 to $12.00. On average, they expect Myomo's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 482.8% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Headlines about MYO stock have been trending very positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Myomo earned a news impact score of 3.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting Myomo?
Myomo saw a decrease in short interest in December. As of December 31st, there was short interest totalling 659,684 shares, a decrease of 18.2% from the December 14th total of 806,700 shares. Based on an average trading volume of 102,310 shares, the days-to-cover ratio is presently 6.4 days. Approximately 6.4% of the company's stock are sold short. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Avacta Group (AVCT), Azure Healthcare (AZV), Cannabix Technologies (BLOZF), Cochlear (COH), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD), Ellex Medical Lasers (ELXMF) and EMvision Medical Devices (EMV).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.63.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
